← Russell 3000 cross-section

FDMT 4D Molecular Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$868m
Revenue TTM
$92m
Net income TTM
$-179m
Free cash flow
Composite score
Sector rank
#2102

Valuation

P / E
EV / EBITDA
EV / sales
5.7
FCF yield
Earnings yield vs 10-yr
-25.36pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-194.7%
EBITDA margin
-208.6%
ROE
-44.0%
ROIC
-299.1%
Revenue growth
278,712.1%

Insider activity, last 90 days

Net open-market
$-3.69m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In addition, we are eligible for up to $335.5 million in potential regulatory and commercial milestone payments and tiered double-digit royalties depending on net sales in the Otsuka Territory. Components of Results of Operations Revenue Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone payments and clinical trial cost sharing and expense reimbursement amounts. …4D Molecular Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →